NASDAQ (NDAQ) Announces Changes to the Nasdaq-100 Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- Nielsen to acquire DoubleVerify in merger deal
- Apollo to acquire easyJet for £5.7B in cash deal
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Trip.com Group (TCOM) Reports Q3 EPS of $0.13
December 15, 2021 5:03 PM ESTTrip.com Group (NASDAQ: TCOM) reported Q3 EPS of $0.13. Revenue for the quarter came in at $831 million.
For earnings history and earnings-related data on Trip.com Group (TCOM) click here.
... MoreIncyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo
December 14, 2021 4:31 PM ESTIncyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura) a topical JAK inhibitor, as a potential treatment for adolescents and adults (age 12 years) with vitiligo. The FDA grants Priority Review to medicines that may offer a major advance in treatment where none currently exists. The Prescription Drug User... More
